Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Astrazeneca (AZN) Share Price

Intraday
Historical

Price	11,876.00p on 09-09-2026 at 06:15:14
Change	0.00p 0%
Buy	12,400.00p
Sell	11,810.00p

Last Trade:	Unknown 0.00 at 11,813.3526p
Day's Volume:	178
Last Close:	11,876.00p
Open:	0.00p
ISIN:	GB0009895292

Day's Range	0.00p - 0.00p
52wk Range:	10,784.00p - 15,730.00p
Market Capitalisation:	£184.18b
VWAP:	12,000.11284p
Shares in Issue:	1.55b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Lower Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Astrazeneca (AZN) Latest Trades
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:04 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:04 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26
Unknown*	0	11,813.3526p	Currency Conversion OTC Trade	07:15:03 - 09-Sep-26

See more Astrazeneca trades

Astrazeneca (AZN) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
8th Sep 2026 (Tue)	11,958.00	12,122.00	11,852.00	11,876.00	2,301,862
7th Sep 2026 (Mon)	11,986.00	12,210.00	11,952.00	12,042.00	1,975,838
4th Sep 2026 (Fri)	12,146.00	12,206.00	11,986.00	12,006.00	2,248,244
3rd Sep 2026 (Thu)	12,066.00	12,290.00	12,018.00	12,146.00	2,393,791
2nd Sep 2026 (Wed)	12,032.00	12,194.00	11,846.00	11,976.00	2,765,667
1st Sep 2026 (Tue)	11,650.00	12,132.00	11,650.00	11,962.00	2,914,001
31st Aug 2026 (Mon)	11,970.00	11,970.00	11,970.00	11,970.00	0
28th Aug 2026 (Fri)	12,200.00	12,200.00	11,960.00	11,970.00	3,627,372
27th Aug 2026 (Thu)	12,194.00	12,236.00	12,066.00	12,114.00	3,580,331
26th Aug 2026 (Wed)	12,450.00	12,462.00	12,214.00	12,234.00	2,783,597
25th Aug 2026 (Tue)	12,220.00	12,476.00	12,124.00	12,476.00	2,035,709
24th Aug 2026 (Mon)	12,182.00	12,204.00	12,016.00	12,110.00	1,791,143
21st Aug 2026 (Fri)	11,926.00	12,242.00	11,926.00	12,240.00	2,343,868
20th Aug 2026 (Thu)	12,162.00	12,162.00	11,844.00	12,088.00	3,148,662
19th Aug 2026 (Wed)	11,858.00	12,140.00	11,834.00	12,050.00	3,132,856
18th Aug 2026 (Tue)	11,558.00	11,846.00	11,548.00	11,806.00	3,193,800
17th Aug 2026 (Mon)	11,550.00	11,690.00	11,488.00	11,560.00	3,230,472
14th Aug 2026 (Fri)	11,610.00	11,650.00	11,404.00	11,460.00	4,271,602
13th Aug 2026 (Thu)	11,706.00	11,746.00	11,604.00	11,708.00	3,381,662
12th Aug 2026 (Wed)	11,786.00	11,796.00	11,612.00	11,702.00	1,676,955
11th Aug 2026 (Tue)	11,980.00	12,056.00	11,840.00	11,844.00	2,712,882
10th Aug 2026 (Mon)	12,030.00	12,060.00	11,856.00	11,990.00	3,814,704

See more Astrazeneca price history

Date	Source	Headline
Astrazeneca (AZN) Regulatory News
8th Sep 2026 2:00 pm	RNS	Imfinzi+Imdelltra improved OS in small cell lung
7th Sep 2026 7:00 am	RNS	Etcamah approved in the US for HR+ breast cancer
1st Sep 2026 3:05 pm	RNS	Admission of Further Securities to Trading
1st Sep 2026 3:00 pm	RNS	Total Voting Rights
1st Sep 2026 11:00 am	RNS	Admission to Trading - €2.55 billion bond offering
1st Sep 2026 7:30 am	RNS	Enhertu approved in EU for 1L HER2-positive mBC
1st Sep 2026 7:10 am	RNS	Directorate change
1st Sep 2026 7:05 am	RNS	AstraZeneca completes agreement for Zegfrovy
1st Sep 2026 7:00 am	RNS	Tagrisso + Orpathys improved PFS in 1L EGFRm lung
27th Aug 2026 7:00 am	RNS	Tezspire CROSSING trial met primary endpoints

See more Astrazeneca regulatory news

Astrazeneca (AZN) Share News

AstraZeneca hails tozorakimab licence application approval in US

8th Sep 2026 14:21

(Alliance News) - AstraZeneca PLC on Tuesday said its biologics licence application for tozorakimab in the US was accepted under priority review. Read More

LONDON BROKER RATINGS: Jefferies raises Autotrader and Rightmove

8th Sep 2026 09:08

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More

IN BRIEF: AstraZeneca wins US nod for Etcamah breast cancer combo

7th Sep 2026 01:08

AstraZeneca PLC - Cambridge, England-based pharmaceuticals firm - Welcomes the US Food & Drug Administration's accelerated approval of Etcamah for use alongside a cyclin‑dependent kinase 4 and 6 inhibitor, a type of medicine that slows cancer cell growth, in adults with advanced hormone‑driven breast cancer. Says Etcamah, which blocks the effect of estrogen on tumour cells, is cleared for patients who develop a mutation in the estrogen receptor 1 gene, a change that can make standard hormone treatment stop working. AstraZeneca says the decision is supported by Serena-6 phase three trial showing the combination keeps the disease from worsening for longer than current first‑line therapy. The firm adds that safety findings are in line with what is already known about the medicines used. Etcamah is also approved in more than 30 countries. Read More

IN BRIEF: Hutchmed "thrilled" by positive phase 3 trial results

1st Sep 2026 13:37

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Announces "positive high-level results" from the Sanovo China phase 3 trial of Orpathys plus Tagrisso in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer, whose tumours harbour epidermal growth factor receptor mutation and MET overexpression. Orpathys, or savolitinib, combined with Tagrisso or osimertinib, showed "a statistically significant and highly clinically meaningful improvement in progression-free survival" in the high MET and intention-to-treat patient populations, compared with Tagrisso alone. Hutchmed adds that "the combination also demonstrated a very encouraging clinical benefit in [the secondary endpoint of] overall survival" in both populations. Hutchmed is jointly developing Orpathys with AstraZeneca, which is also commercialising the treatment. Read More

UK dividends calendar - next 7 days

1st Sep 2026 13:35

See more Astrazeneca news

FTSE 100 Latest

Value10,811.66

Change0.00

Astrazeneca (AZN) Share Price

Login to your account